TNFRSF8 and Hodgkins lymphoma: Most impressively, brentuximab vedotin, which consists of a CD30-targeting antibody conjugated to the tubulin binder monomethyl auristatin E, was shown to be safe and effective for children with relapsed/refractory CD30+ Hodgkin lymphoma or systemic anaplastic lymphoma (Locatelli et al. 2018).